Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADC Therapeutics SAADCT · Entity 6502 | Director | June 01, 2026 | June 03, 2026 |
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director | June 07, 2024 | June 11, 2024 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Financial Officer | February 06, 2017 | February 09, 2017 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | June 12, 2026 | June 16, 2026 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | June 09, 2026 | June 10, 2026 |
| aTYR PHARMA INCATYR · Entity 7233 | Director | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADC Therapeutics SA
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 72,400 |
Ending reported balance
After 2026-06-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-01 · Grant · Acquired 45,000 · Balance 85,000 F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-06-03 · Tax withholding · Disposed 12,600 · Balance 72,400 F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.
FATE THERAPEUTICS INC
Report date June 07, 2024 · Filed June 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2034-06-07 | Direct | 40,000 |
Reported balance
After 2024-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-07 · Grant · Acquired 40,000 · Balance 40,000 F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
NEUROCRINE BIOSCIENCES INC
Report date February 06, 2017 · Filed February 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,961 |
Reported balance
After 2017-02-06 transaction · row 1
1 source rowRow 1 · 2017-02-06 · Sale · Disposed 963 · Balance 137,961 F1: Sale of 963 shares of common stock issued upon vesting of 2550 restricted stock units to cover withholding taxes with the balance of the shares (1587) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of 963 shares of common stock issued upon vesting of 2550 restricted stock units to cover withholding taxes with the balance of the shares (1587) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Travere Therapeutics, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,250 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-12 · Exercise / conversion · Acquired 10,000 · Balance 66,250 Row 2 · 2026-06-12 · Sale · Disposed 10,000 · Balance 56,250 F1: This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2: The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.52 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Exercise / conversion · Disposed 10,000 · Balance 0 F3: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2: The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The stock option is fully vested and exercisable.
Vir Biotechnology, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,000 |
Ending reported balance
After 2026-06-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-09 · Grant · Acquired 8,000 · Balance 8,000 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: 1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest in two equal annual installments thereafter. Row 2 · 2026-06-09 · Grant · Acquired 8,000 · Balance 16,000 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F3: The RSUs will vest in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.51 · Expires 2036-06-08 | Direct | 16,000 |
Reported balance
After 2026-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-09 · Grant · Acquired 16,000 · Balance 16,000 F4: 1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027, and the remaining shares will vest and become exercisable in 24 equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.51 · Expires 2036-06-08 | Direct | 16,000 |
Reported balance
After 2026-06-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-09 · Grant · Acquired 16,000 · Balance 16,000 F5: The shares subject to the stock option vest and become exercisable in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2: 1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest in two equal annual installments thereafter.
F3: The RSUs will vest in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.
F4: 1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027, and the remaining shares will vest and become exercisable in 24 equal monthly installments thereafter.
F5: The shares subject to the stock option vest and become exercisable in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.
aTYR PHARMA INC
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-11 | Direct | 50,000 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Grant · Acquired 50,000 · Balance 50,000 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2020 Filed May 5, 2020 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 16,000 | Not disclosed Strike: $26.59 | Not disclosed |
DisclosureSEC source: 0001209191-20-027069 · doc4.xml · derivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-05-01 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 1, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:34 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029153 · doc4.xml · derivative · entry 2 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:34 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029153 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:06 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001209191-19-029011 · doc4.xml · derivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 8, 2020 or (ii) the Issuer's 2020 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 03, 2019 Filed May 7, 2019 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 16,000 | Not disclosed Strike: $17.15 | Not disclosed |
DisclosureSEC source: 0001209191-19-027945 · doc4.xml · derivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-05-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 3, 2020 or (ii) the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:23 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-18-030907 · doc4.xml · derivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-15 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 15, 2019 or (ii) the Issuer's 2019 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 09, 2018 Filed May 12, 2018 01:09 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $26.52 | $0.00 |
DisclosureSEC source: 0001209191-18-029723 · doc4.xml · derivative · entry 2 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-08 F1 · derivative.exercise_date: The option shall vest in 4 equal quarterly installments following the date of grant. Read SEC document |
| May 09, 2018 Filed May 12, 2018 01:09 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-029723 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:16 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 16,000 | Not disclosed Strike: $9.78 | Not disclosed |
DisclosureSEC source: 0001209191-18-028099 · doc4.xml · derivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-05-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 2, 2019 or (ii) the date of the 2019 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:17 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001209191-17-033720 · doc4.xml · derivative · entry 2 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option shall vest in 4 equal quarterly installments following the date of grant. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:17 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033720 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:54 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-17-031635 · doc4.xml · derivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| May 02, 2017 Filed May 4, 2017 15:56 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $4.73 | Not disclosed |
DisclosureSEC source: 0001209191-17-029928 · doc4.xml · derivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-01 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 2, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| April 07, 2017 Filed Apr 10, 2017 21:29 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001209191-17-026450 · doc4.xml · derivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2027-04-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning May 7, 2017, such that this option will fully exercisable on April 7, 2020, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:39 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 963 | $43.14 | $41,543.82 |
DisclosureSEC source: 0001209191-17-008909 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,961 F1 · kind: Sale of 963 shares of common stock issued upon vesting of 2550 restricted stock units to cover withholding taxes with the balance of the shares (1587) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,500 | $42.55 | $63,825.00 |
DisclosureSEC source: 0001209191-17-008136 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,324 F1 · kind: Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 3, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.80 to $43.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,750 | $40.65 | $71,137.50 |
DisclosureSEC source: 0001209191-17-004305 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,824 F1 · kind: Sale of 1,750 shares of common stock issued upon vesting of 3,500 restricted stock units on January 17, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $39.91 to $41.73. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 23:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,750 | $43.37 | $75,897.50 |
DisclosureSEC source: 0001209191-17-003584 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,124 F1 · kind: Sale of 1,750 shares of common stock issued upon vesting of 3,500 restricted stock units on January 10, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.50 to $45.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 20:42 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | PurchaseCommon Stock | 56,390 | $2.66 | $149,997.40 |
DisclosureSEC source: 0001209191-16-152153 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,390 F1 · shares: Represents shares acquired in a private placement pursuant to the Securities Purchase Agreement dated November 21, 2016 by and among the issuer and the purchasers named therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.